内源性大麻素系统与骨代谢

摘要/Abstract

摘要： 内源性大麻素系统是包括了内源性大麻素、大麻素受体(CB)以及相关酶的一个复杂的生理系统。近年来内源性大麻素系统与骨代谢的关系被一步步证实。大量研究发现CB-1受体及CB-2受体存在于骨细胞中，并在骨代谢的过程中起到不同的作用。其余受体包括TPRV1、GPR55、GPR119、TPRV4等，亦参与了骨代谢的过程。以anandamide和2-arachidonoylglycerol为代表的内源性大麻素以及其激动剂和拮抗剂可以通过大麻素受体的介导影响成骨细胞与破骨细胞的增殖分化及骨重塑。可见内源性大麻素系统可作为骨再生治疗的新靶点，然而目前尚无足够数量的相关临床数据，因此大麻素与骨代谢的关系值得进一步研究。

关键词: 大麻素, 大麻素受体, 内源性大麻素, 内源性大麻素系统, 骨代谢

Abstract: The endocannabinoid system is a complex physiological system, consisting of endocannabinoid and the enzymes involved in their biosynthesis and degradation as well as the cannabinoid receptors. Recent researches have confirmed the relationship between endocannabinoid system and bone metabolism. Studies show that CB-1 and CB-2 receptors, two of the most important receptors, are found in bone cells and have different effects on bone metabolism. In addition, other receptors such as TPRV1, GPR55, GPR119, and TPRV4 are involved in bone metabolism, too. Anandamide and 2-arachidonoylglycerol, two typical endocannabinoids, and their agonists and antagonist regulate osteoblast and osteoclast's differentiation and proliferation as well as bone remodeling through the mediation of cannabinoid receptors. It is thus clear that the endocannabinoid system is a potential target for future treatment to increase bone regeneration. Prospective studies on the relationship between the endocannabinoid system and bone metabolism are needed.

Key words: cannabinoids, cannabinoid receptors, endocannabinoids, endocannabinoid system, bone metabolism

中图分类号:

R366

丁鼎王柏翔周益. 内源性大麻素系统与骨代谢[J]. 口腔医学, 2021, 41(9): 839-842.

参考文献 42

[1]	FRAGUAS-SáNCHEZ A I, TORRES-SUáREZ A I.Medical Use of Cannabinoids[J].Drugs, 2018, 78(16):1665-1703
[2]	PAGOTTO U, MARSICANO G, COTA D, et al.The emerging role of the endocannabinoid system in endocrine regulation and energy balance[J].Endocrine Reviews, 2006, 27(1):73-100
[3]	LAPRAIRIE R B, BAGHER A M, DENOVAN-WRIGHT E M.Cannabinoid receptor ligand bias: implications in the central nervous system[J].Current Opinion in Pharmacology, 2017, 32:32-43
[4]	KATCHAN V, DAVID P, SHOENFELD Y.Cannabinoids and autoimmune diseases: A systematic review[J].Autoimmunity Reviews, 2016, 15(6):513-528
[5]	SCHERMA M, MASIA P, SATTA V, et al.Brain activity of anandamide?: a rewarding bliss??[J].Acta Pharmacologica Sinica, 2019, 40(3):309-323
[6]	AYMEN I IDRIS, ROBERT J VAN’T HOF, IAIN R GREIG, SUSAN A RIDGE, DAVID BAKER, RUTH A ROSS S H R.Regulation of bone mass,bone loss and osteoclast activity by cannabinoid receptors[J].Nat Med, 2005, 23(1):1-7
[7]	SHARMA C, SADEK B, GOYAL S N, et al.Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors?: Potential Leads for Drug Discovery and Development[J]. Evidence-Based Complementary and Alternative Medicine, 2015, 2015.
[8]	MACKIE K.Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System[J]. Cannabinoids, 2005, 168: 299-325
[9]	TAM J, OFEK O, FRIDE E, et al.Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling[J].Molecular Pharmacology, 2006, 70(3):786-792
[10]	IDRIS A I, SOPHOCLEOUS A, LANDAO-BASSONGA E, et al.Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells[J].Cell Metabolism, 2009, 10(2):139-147
[11]	SAMIR S M, MALEK H A.Effect of cannabinoid receptors 1 modulation on osteoporosis in a rat model of different ages[J].Journal of Physiology and Pharmacology, 2014, 65(5):687-694
[12]	GALVE-ROPERH I, CHIURCHIù V, DíAZ-ALONSO J, et al.Cannabinoid receptor signaling in progenitorstem cell proliferation and differentiation[J].Progress in Lipid Research, 2013, 52(4):633-650
[13]	EGER M, BADER M, BREE D, et al.Bone Anabolic Response in the Calvaria Following Mild Traumatic Brain Injury is Mediated by the Cannabinoid-1 Receptor[J].Scientific Reports, Springer US, 2019, 9(1):1-8
[14]	IDRIS A I.The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease[J]. BoneKEy, 2011, 8: 84.
[15]	PREEDY, VICTOR R.ed. Handbook of Cannabis on PPAR activationby cannabinoids[M]. Handbook of Cannabis and Related Pathologies, 2016.
[16]	RALSTON S H.Genetic Background Modifies the Effects of Type 2 Cannabinoid Receptor Deficiency on Bone Mass and Bone Turnover[J].Calcified tissue international, 2014, 94(3):259-268
[17]	CARNOVALI M, OTTRIA R, PASQUALETTI S, et al.Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease[J]. Pharmacological research, 2016, 104: 1-8.
[18]	QIAN H, ZHAO Y, PENG Y, et al.Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells[J].Journal of Periodontal Research, 2010, 45(4):504-511
[19]	APOSTU D, LUCACIU O, MESTER A, et al.Cannabinoids and bone regeneration[J].Drug metabolism reviews, 2019, 51(1):65-75
[20]	XU A, YANG Y, SHAO Y, et al.Activation of cannabinoid receptor type 2-induced osteogenic differentiation involves autophagy induction and p62-mediated Nrf2 deactivation[J].Cell Communication and Signaling, 2020, 18(1):1-11
[21]	IDRIS A I, SOPHOCLEOUS A, LANDAO-BASSONGA E, et al.Regulation of bone mass,osteoclast function,and ovariectomy-induced bone loss by the type 2 cannabinoid receptor[J].Endocrinology, 2008, 149(11):5619-5626
[22]	OFEK O, KARSAK M, LECLERC N, et al.Peripheral cannabinoid receptor,CB2,regulates bone mass[J].Proceedings of the National Academy of Sciences, 2006, 103(3):696-701
[23]	KHALID A B, GOODYEAR S R, ROSS R A, et al.Effects of deleting cannabinoid receptor-2 on mechanical and material properties of cortical and trabecular bone[J].Cogent Engineering, Cogent, 2015, 138(1):1-9
[24]	SOPHOCLEOUS A, MARINO S, KABIR D, et al.Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition[J].Aging Cell, 2017, 16(5):1051-1061
[25]	MARZO V Di, CRISTINO L.Why endocannabinoids are not all alike[J].Nature neuroscience, 2008, 11(2):124-126
[26]	MANUSCRIPT A.The history of the Drosophila TRP channel: The birth of a new channel superfamily[J].Journal of neurogenetics, 2010, 24(4):216-233
[27]	KANAYA K, IBA K, DOHKE T, et al.TRPV1,ASICs and P2X23 expressed in bone cells simultaneously regulate bone metabolic markers in ovariectomized mice[J].Journal of musculoskeletal & neuronal interactions, 2016, 16(2):145-
[28]	ROSSI F, BELLINI G, TORTORA C, et al.CB2 and TRPV1 receptors oppositely modulate in vitro human osteoblast activity[J]. Pharmacological research, 2015, 99: 194-201.
[29]	ROSSI F, TORTORA C, PUNZO F, et al.The Endocannabinoid Endovanilloid System in Bone[J].International journal of molecular sciences, 2019, 20(8):1919-
[30]	HE L, LIU M, HE Y, et al.TRPV1 deletion impaired fracture healing and inhibited osteoclast and osteoblast differentiation[J]. Scientific reports, 2017, 7: 42385.
[31]	HU K, SUN H, GUI B, et al.TRPV4 functions in flow shear stress induced early osteogenic differentiation of human bone marrow mesenchymal stem cells[J]. Biomedicine & Pharmacotherapy, 2017, 91: 841-848.
[32]	KIM H J, YOON H J, PARK J W, et al.G protein-coupled receptor 119 is involved in RANKL-induced osteoclast differentiation and fusion[J].Journal of Cellular Physiology, 2019, 234(7):11490-11499
[33]	WHYTE L S, RYBERG E, SIMS N A, et al.The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo[J].Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(38):16511-16516
[34]	WHYTE L S, FORD L, RIDGE S A, et al.Cannabinoids and bone: Endocannabinoids modulate human osteoclast function in vitro[J].British Journal of Pharmacology, 2012, 165(8):2584-2597
[35]	SMITH M, WILSON R, O’BRIEN S, et al.The effects of the endocannabinoids anandamide and 2-arachidonoylglycerol on human osteoblast proliferation and differentiation[J].PLoS ONE, 2015, 10(9):1-15
[36]	IDRIS A I, RALSTON S H.Role of cannabinoids in the regulation of bone remodeling[J]. Frontiers in Endocrinology, 2012, 3:136.
[37]	BAB I, ZIMMER A, MELAMED E.Cannabinoids and the skeleton: From marijuana to reversal of bone loss[J].Annals of Medicine, 2009, 41(8):560-567
[38]	SCUTT A, WILLIAMSON E M.Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors[J].Calcified Tissue International, 2007, 80(1):50-59
[39]	JIANG H, WU Y, VALVERDE P, et al.Central Adiponectin Induces Trabecular Bone Mass partly through Epigenetic downregulation of Cannabinoid Receptor CB1[J].Journal of cellular physiology, 2019, 234(5):7062-7069
[40]	DOU Z jun, GAO X L, JIA Y li, et al.CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats[J]. Sleep and Breathing, 2020, 1-9.
[41]	PROTO M C, FIORE D, PISCOPO C, et al.Inhibition of Wntβ-Catenin pathway and Histone acetyltransferase activity by Rimonabant: A therapeutic target for colon cancer[J].Scientific Reports, 2017, 7(1):1-14
[42]	SMOUM R, BARAGHITHY S, CHOURASIA M, et al.CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency[J].Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(28):8774-8779